Clinical trials: Idiopathic Pulmonary Fibrosis(IPF)
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF
The purpose of this study is to test cough, dyspnea (shortness of breath), and quality of life (QOL) questionnaires for their accuracy, sensitivity, and ability to reliably measure the severity of cough, breathlessness, and…
- Trial name
- NCT01874223
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
IPF
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis
This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07519070
- Testing
- HSK44459
- Volunteers
- 420 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder)
Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography
Lung involvement is one of the most frequent extra articular involvements of rheumatoid arthritis (RA). RA related lung involvement can affect parenchyma, airway, vascular tree and serosa.
- Conditions
- Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), Idiopathic Pulmonary Fibrosis (IPF), Connective Tissue Disease (CTD)
- Trial name
- NCT07174102
- Testing
- High resolution computed tomography
- Where
- 5 sites in Czechia, Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis
This study measures the 4 metre gait speed (4MGS) test in patients with Idiopathic Pulmonary Fibrosis (IPF). The investigators are interested to see whether usual walking speed in IPF patients changes following pulmonary…
- Trial name
- IPFRESP (NCT02530736)
- Testing
- 4 metre gait speed
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a biomarker in interstitial lung disease.
- Trial name
- NCT04677426
- Testing
- Hyperpolarized Xe129
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult..
- Trial name
- NCT05657184
- Testing
- REGEND001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
- Trial name
- AF-BMC (NCT07332117)
- Testing
- No Interventions, No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment…
- Trial name
- NCT02788474
- Testing
- nintedanib
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 347 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the…
- Trial name
- NCT05424887
- Testing
- AK3280
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
- Trial name
- PIPF-012 (NCT00662038)
- Testing
- pirfenidone
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- IPF (NCT07728721)
- Testing
- HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3
- Volunteers
- 175 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Interstitial Lung Disease
Specific Autoantibody Testing in Patients With Interstitial Lung Disease
The purpose of this study is to evaluate the clinical utility of specific autoantibody testing in unmasking an underlying connective tissue disorder in patients who present with interstitial lung disease and found to have weak…
- Trial name
- NCT01600352
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore General Hospital
Lung Cancer and Idiopathic Pulmonary Fibrosis
Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers.
- Trial name
- K-FPI (NCT03486262)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis(IPF)
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui…
- Trial name
- NCT06914713
- Testing
- Jin-shui Huan-xian granule
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes.
- Conditions
- Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
- Trial name
- NCT00470327
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Idiopathic Interstitial Pneumonia
Japanese Idiopathic Interstitial Pneumonias Registry
An objective of JIPS Registry is to examine disease behavior of idiopathic interstitial pneumonias (IIPs), considering classification, background, and diagnostic methods based on American Thoracic Society (ATS)/ European…
- Trial name
- JIPS (NCT03041623)
- Where
- 86 sites in Japan
- Volunteers
- 867 people
- Sponsor
- North East Japan Study Group
Idiopathic Pulmonary Fibrosis
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02477709
- Testing
- Gefapixant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)